Novo Nordisk A/S (NYSE:NVO)’s share price hit a new 52-week low during mid-day trading on Friday . The stock traded as low as $45.88 and last traded at $45.97, with a volume of 7,375,222 shares changing hands. The stock had previously closed at $46.46.

Several brokerages have issued reports on NVO. Citigroup Inc. reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Wednesday, August 3rd. Zacks Investment Research cut shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research note on Monday, July 4th. Goldman Sachs Group Inc. cut shares of Novo Nordisk A/S from a “conviction-buy” rating to a “buy” rating in a research note on Tuesday, June 28th. Finally, Bank of America Corp. cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Monday, August 8th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and two have given a strong buy rating to the company’s stock. Novo Nordisk A/S presently has an average rating of “Buy” and an average price target of $61.00.

The firm has a 50-day moving average price of $53.57 and a 200-day moving average price of $54.05. The company has a market cap of $117.13 billion and a price-to-earnings ratio of 21.94.

The company also recently disclosed a dividend, which will be paid on Tuesday, August 23rd. Investors of record on Monday, August 15th will be paid a dividend of $0.326 per share. The ex-dividend date of this dividend is Thursday, August 11th.

An institutional investor recently raised its position in Novo Nordisk A/S stock. Bank of Montreal Can boosted its stake in Novo Nordisk A/S (NYSE:NVO) by 16.1% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 64,142 shares of the company’s stock after buying an additional 8,892 shares during the period. Bank of Montreal Can’s holdings in Novo Nordisk A/S were worth $3,726,000 as of its most recent SEC filing.

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.